Quick Answer
Celldex Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $1.55 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed a decrease of -78.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $1.53 million | Q2 2017: $3.83 million | Q3 2017: $3.92 million | Q1 2018: $4.07 million | Q2 2018: $2.76 million | Q3 2018: $941.0 thousand | Q4 2018: $1.76 million | Q1 2019: $1.43 million | Q2 2019: $715.0 thousand | Q3 2019: $546.0 thousand | Q4 2019: $887.0 thousand | Q1 2020: $2.73 million | Q2 2020: $236.0 thousand | Q3 2020: $668.0 thousand | Q4 2020: $3.79 million | Q1 2021: $685.0 thousand | Q2 2021: $3.48 million | Q3 2021: $153.0 thousand | Q1 2022: $174.0 thousand | Q2 2022: $163.0 thousand | Q3 2022: $407.0 thousand | Q1 2023: $967.0 thousand | Q2 2023: $268.0 thousand | Q3 2023: $1.52 million | Q1 2024: $156.0 thousand | Q2 2024: $2.50 million | Q3 2024: $3.19 million | Q1 2025: $695.0 thousand | Q2 2025: $730.0 thousand.
- Over the full 10 years of available data (2016 to 2025), Celldex Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 77.2%.
- Historical annual values: Fiscal year 2025: $1.55 million | Fiscal year 2024: $7.02 million | Fiscal year 2023: $6.88 million | Fiscal year 2022: $2.36 million | Fiscal year 2021: $4.65 million | Fiscal year 2020: $7.42 million | Fiscal year 2019: $3.57 million | Fiscal year 2018: $9.54 million | Fiscal year 2017: $12.74 million | Fiscal year 2016: $6.79 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: